EGFR and hepatocellular carcinoma: Among them, 6 articles including 6 studies with 839 patients, 4 articles containing 5 studies with 604 patients and one article containing 1 studies with 89 patients investigating the association between BIM polymorphism and clinical outcome of EGFR-TKI, imatinib as well sorafenib for EGFR-mutated NSCLC, CML and HCC, respectively.